MoneyWorks4Me

Venus Remedies - Quaterly Results

26 May 2025 Evaluate
The March 2025 quarter revenue stood at Rs. 1940.40 millions, up 10.78% as compared to Rs. 1751.60 millions during the corresponding quarter last year.Modest increase of 18.23% in the Net Profit was reported from. 125.10 millions to Rs. 147.90  millions.Operating profit for the quarter ended March 2025 rose to 293.20 millions as compared to 251.90 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 1940.40 1751.60 10.78 6394.60 5752.10 11.17 6394.60 5752.10 11.17
Other Income 67.70 39.10 73.15 207.80 113.20 83.57 207.80 113.20 83.57
PBIDT 293.20 251.90 16.40 907.70 722.00 25.72 907.70 722.00 25.72
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT 293.20 251.90 16.40 1006.80 722.00 39.45 1006.80 722.00 39.45
Depreciation 44.90 57.20 -21.50 216.20 255.50 -15.38 216.20 255.50 -15.38
PBT 248.30 194.70 27.53 790.60 466.50 69.47 790.60 466.50 69.47
TAX 100.40 69.60 44.25 265.10 161.50 64.15 265.10 161.50 64.15
Deferred Tax 18.30 15.80 15.82 46.50 39.30 18.32 46.50 39.30 18.32
PAT 147.90 125.10 18.23 525.50 305.00 72.30 525.50 305.00 72.30
Equity 133.70 133.70 0.00 133.70 133.70 0.00 133.70 133.70 0.00
PBIDTM(%) 15.11 14.38 5.07 14.19 12.55 13.09 14.19 12.55 13.09
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..